

Milton Keynes Community Health Services



NHS

COPD (patients with no asthmatic features) – first line inhaler options

Use <u>SABAs</u> (Salbutamol MDI or DPI) as required as the initial treatment to relieve breathlessness & exercise limitation. <u>SABAs</u> can continue at all stages. If appropriate <u>STOP</u> SAMA when starting LAMA .				
	Mild Symptoms	Moderate Symptoms	Severe/Very Severe Symptoms	
Inhaler options	LAMA (Treatment options if still breathless despite SABA treatment)	LAMA + LABA (Combination) (Treatment options if persistent dyspnoea &/or exacerbations)	LABA + ICS + LAMA (Triple therapy combo) (Persistent symptoms/further exacerbation(s))	
MDI (preferred Choice)	Spiriva <u>Respimat</u> (Tiotropium) <i>(Aerosol)</i> 2.5mcg	Spiolto <u>Respimat</u> (Tiotropium & Olodaterol) 2.5mcg/2.5mcg	If exacerbations / breathlessness continues, consider referral to <u>AIRS /</u> <u>PCOC</u> service for specialist review	
DPI (preferred Choice)	Braltus <u>Zonda inhaler</u> (Tiotropium) capsules 10mcg	Duaklir <u>Genuair</u> (Aclidinium & Formoterol) 340mcg/12mcg	to explore further options including initiation of triple therapy if appropriate.	
DPI	Eklira <u>Genuair</u> (Aclidinium) 322mcg	Duaklir <u>Genuair</u> (Aclidinium & Formoterol) 340mcg/12mcg	Trimbow <u>MDI</u> (Formoterol / Beclometasone / Glycopyrronium) 5mcg/87mcg/9mcg	
DPI	Incruse <u>Ellipta</u> (Umeclidinium) 55mcg	Anoro <u>Ellipta</u> (Vilanterol & Umeclidinium) 55mcg/22mcg	Trelegy <u>Ellipta</u>	
DPI	Seebri <u>Breezhaler</u> (Glycopyrronium) 44mcg	Ultibro <u>Breezhaler</u> (Indacaterol & Glycopyrronium) 85mcg/43mcg	(Vilanterol/Fluticasone furoate /Umeclidinium) 22mcg/92mcg/55mcg	

COPD (ACO) (patients with asthmatic features) - first line inhaler options

Consider LABA+ICS for people who: have spirometrically confirmed COPD <u>AND</u> have asthmatic features/features suggesting steroid responsiveness. Be aware of, and be prepared to discuss with the person, the risk of side effects (including pneumonia) in people who use inhaled corticosteroids.

Inhaler options	LABA + ICS (Treatment options if still breathless despite SABA treatment)	LABA + ICS + LAMA (Triple therapy combo) (Remains breathless or has exacerbations despite taking LABA+ICS)	
MDI (preferred Choice)	Fostair <u>MDI</u> (Formoterol / Beclometasone) 6mcg/ 100mcg	Trimbow MDI (Formoterol / Beclometasone / Glycopyrronium) 5mcg/87mcg/9mcg	
DPI (preferred Choice)	Fostair <u>NEXThaler</u> (Formoterol / Beclometasone) 6mcg/ 100mcg	Trelegy <u>Ellipta</u> (Vilanterol/Fluticasone furoate/Umeclidinium) 22mcg/92mcg/55mcg	
DPI	Relvar <u>Ellipta</u> (Vilanterol/ Fluticasone furoate) 22mcg / 92mcg	Trelegy <u>Ellipta</u> (Vilanterol/Fluticasone furoate/Umeclidinium) 22mcg/92mcg/55mcg	
DPI	Symbicort <u>Turbohaler</u> (Formoterol / Budesonide) 6mcg/ 200mcg	Trelegy <u>Ellipta</u> (Vilanterol/Fluticasone furoate/Umeclidinium) 22mcg/92mcg/55mcg	
DPI	Fobumix <u>Easyhaler</u> (Formoterol fumarate / budesonide) 9mcg/ 320mcg	Trelegy <u>Ellipta</u> (Vilanterol/Fluticasone furoate/Umeclidinium) 22mcg/92mcg/55mcg	

For ALL inhaled therapies: Review is essential before changing inhalers. In mild COPD evidence is poor for triple therapy. Teach people in correct inhaler technique, and review medication and assess inhaler technique and adherence regularly (Top tip:- ask them to show you how they use their inhalers / use In-Check device to teach correct inspiratory flow for the device) <u>REMEMBER:</u> Tell them to rinse, gargle and spit after using inhalers to reduce side effects e.g. oral thrush (do not just have a drink!) <u>CAUTION:</u> Avoid duplication e.g. LAMA and LABAs in combination products (know the ingredients in the branded products) LAMAs - Caution with cardiac disease / renal impairment – see SPCs